The costs associated with ankylosing spondylitis/axial spondyloarthritis in Aotearoa/New Zealand.
CONCLUSIONS: This study has quantified the direct and indirect costs of spondyloarthritis (SpA) in Aotearoa/New Zealand, and demonstrates meaningful reduction in quality of life and work productivity in patients with SpA. The major driver of direct costs in SpA are biologic medications.
PMID: 31697662 [PubMed - in process]
Source: New Zealand Medical Journal - Category: General Medicine Tags: N Z Med J Source Type: research
More News: Ankylosing Spondylitis | General Medicine | Legislation | New Zealand Health | Pain | Study